[Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?]

Gábor Simonyi1

  • 1Szent Imre Egyetemi Oktatókórház Anyagcsere Központ Budapest Tétényi út 12-16. 1115.

Orvosi Hetilap
|October 15, 2013
PubMed

Insights

Hypertension is a common chronic disease and cardiovascular risk factor in Hungary. Ramipril/amlodipine fixed combination offers favorable patient adherence and meets key criteria for antihypertensive drugs.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Context:

  • Hypertension is a prevalent chronic disease in Hungary, significantly contributing to cardiovascular morbidity and mortality.
  • Effective blood pressure control is crucial for reducing risks of stroke, coronary artery disease, and renal disease, especially in high-risk individuals.
  • Patient adherence to antihypertensive medication regimens is influenced by drug complexity, class, age, and gender.

Purpose:

  • To evaluate the suitability of antihypertensive drugs based on metabolic neutrality and cardiovascular protective effects.
  • To assess the adherence profile of a fixed-dose combination of ramipril/amlodipine in managing hypertension.

Summary:

  • Antihypertensive medications are essential for managing hypertension, alongside lifestyle modifications.
  • Drugs with metabolically neutral properties and cardiovascular benefits are preferred.
  • The fixed combination of ramipril/amlodipine demonstrates favorable adherence and meets these desirable pharmacological criteria.

Impact:

  • Optimizing antihypertensive drug selection can improve patient outcomes and reduce the burden of cardiovascular disease.
  • Favorable adherence to medications like ramipril/amlodipine fixed combination can lead to better blood pressure control.
  • This research supports the use of specific antihypertensive combinations for improved patient management and reduced cardiovascular risk.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
642
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K